Montelukast Noridem Enterprises (Montelukast)

Montelukast works by selectively blocking the cysteinyl leukotriene receptor CysLT1. This prevents leukotriene D4 and related mediators from causing bronchoconstriction, mucus production and airway inflammation, thereby improving breathing and reducing allergic symptoms.

The dose of Montelukast is determined by the prescribing clinician based on the patient’s age, weight, severity of disease and response to therapy. The prescriber will select the appropriate strength and dosing schedule for each individual.

The safety of Montelukast in pregnancy and lactation has not been definitively established. Healthcare providers should weigh the potential benefits against any possible risks and discuss alternative options when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with aspirin‑sensitive asthma or those who need additional control beyond inhaled therapy, but it does not replace rescue bronchodilators.

Montelukast tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Montelukast is taken orally, usually as a whole tablet with or without food. The exact timing (morning or evening) is decided by the prescriber based on the patient’s treatment plan.

Serious risks include rare neuropsychiatric events such as depression or suicidal thoughts, severe allergic reactions like anaphylaxis, and angioedema. Patients should seek immediate medical attention if they experience mood changes, swelling of the face or throat, or any signs of an allergic reaction.

Montelukast should be avoided in individuals with a known hypersensitivity to the drug or any of its tablet excipients. It is also contraindicated in patients who have experienced severe allergic reactions to leukotriene receptor antagonists.